JAC-2017-0346 revision_FINAL_03MAY17.pdf (694.14 kB)
Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life
journal contribution
posted on 2023-06-09, 06:51 authored by Mark H Wilcox, Harblas Ahir, John E Coia, Andrew Dodgson, Susan Hopkins, Martin LlewelynMartin Llewelyn, Chris Settle, Susan Mclain-Smith, Stephen W MarcellaObjectives: Data quantifying outcomes of recurrent Clostridium difficile infection (rCDI) are lacking. We sought to determine the UK hospital resource use and health-related quality of life (HrQoL) associated with rCDI hospitalisations. Patients and methods: A non-interventional study in 6 UK acute hospitals collected retrospective clinical and resource use data from medical records of 64 adults hospitalised for rCDI and 64 matched inpatient controls with a first episode only (f)CDI. Patients were observed from the index event (date rCDI/fCDI confirmed) for 28-days (or death, if sooner); UK-specific reference costs were applied. HrQoL was assessed prospectively in a separate cohort of 30 patients hospitalised with CDI, who completed the EQ-5D-3L questionnaire during their illness. Results: The median total management cost (post-index) was £7,539 and £6,294 for rCDI and fCDI, respectively (cost difference, p=0.075); median length of stay (LOS) was 21 days and 15.5 days, respectively (p=0.269). The median cost difference between matched rCDI and fCDI cases was £689 (IQR=£-1,873-£3,954). Subgroup analysis demonstrated the highest median costs (£8,542/patient) in severe rCDI cases. CDI management costs were driven primarily by hospital LOS, which accounted for >85% of costs in both groups. Mean EQ-5D index values were 46% lower in CDI patients compared with UK population values (0.42 and 0.78, respectively); EQ-VAS scores were 38% lower (47.82 and 77.3, respectively). Conclusions: CDI has considerable impact on patients and healthcare resources. This multicentre study provides a contemporaneous estimate of the real-world UK costs associated with rCDI management, which are substantial and comparable to fCDI costs.
History
Publication status
- Published
File Version
- Accepted version
Journal
Journal of Antimicrobial ChemotherapyISSN
0305-7453Publisher
Oxford University PressExternal DOI
Issue
9Volume
72Page range
2647-2656Department affiliated with
- Global Health and Infection Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2017-06-22First Open Access (FOA) Date
2018-06-14First Compliant Deposit (FCD) Date
2017-06-22Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC